Trending...
- California: Governor Newsom announces judicial appointments 12.22.2025
- PODS Local Helps Residents Meet Their 2026 New Year's Resolution
- Leimert Park Announces Weeklong Kwanzaa Festival & Kwanzaa Parade Celebrating Black History, Culture, and Community
REDWOOD CITY, Calif., June 1, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the use in medically supervised settings, today announced that management will be providing an overview of the business and company updates at the Jeffries Virtual Healthcare Conference to be held June 2 at 1:30 p.m. ET (10:30 a.m. PT). A live webcast link of the event can be found on the Company's website at http://ir.acelrx.com/upcoming-events. Management will also be hosting one-on-one investor meetings throughout the day.
For those not available to listen to the live webcast, a replay will be archived for 90 days and available through the Investors page on www.acelrx.com.
More on The Californer
About AcelRx Pharmaceuticals, Inc.
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. AcelRx's proprietary, non-invasive sublingual formulation technology delivers sufentanil with consistent pharmacokinetic profiles. The Company has one approved product in the U.S., DSUVIA® (sufentanil sublingual tablet, 30 mcg), known as DZUVEO in Europe, indicated for the management of acute pain severe enough to require an opioid analgesic for adult patients in certified medically supervised healthcare settings, and one product candidate, Zalviso® (sufentanil sublingual tablet system, SST system, 15 mcg) being developed as an innovatively designed patient-controlled analgesia (PCA) system for reduction of moderate-to-severe acute pain in medically supervised settings. DZUVEO and Zalviso are both approved products in Europe. Zalviso is not approved in the U.S. For additional information about AcelRx, please visit www.acelrx.com.
SOURCE AcelRx Pharmaceuticals, Inc.
Related Links
www.acelrx.com
For those not available to listen to the live webcast, a replay will be archived for 90 days and available through the Investors page on www.acelrx.com.
More on The Californer
- US Van Rental Expands Group Transportation Services Across Los Angeles
- GIFTAWAY's Wood Wick Candle Collection Sets the Tone for the New Year
- Inclusive Hip-Hop Dance Class with Culture Shock Celebrates Movement Without Limits
- Long Beach: El Dorado Nature Center to Hold New Year, New Use Recycling Drive
- UK Financial Ltd Executes Compliance Tasks Ahead Of First-Ever ERC-3643 Exchange-Traded Token, SMCAT & Sets Date For Online Investor Governance Vote
About AcelRx Pharmaceuticals, Inc.
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. AcelRx's proprietary, non-invasive sublingual formulation technology delivers sufentanil with consistent pharmacokinetic profiles. The Company has one approved product in the U.S., DSUVIA® (sufentanil sublingual tablet, 30 mcg), known as DZUVEO in Europe, indicated for the management of acute pain severe enough to require an opioid analgesic for adult patients in certified medically supervised healthcare settings, and one product candidate, Zalviso® (sufentanil sublingual tablet system, SST system, 15 mcg) being developed as an innovatively designed patient-controlled analgesia (PCA) system for reduction of moderate-to-severe acute pain in medically supervised settings. DZUVEO and Zalviso are both approved products in Europe. Zalviso is not approved in the U.S. For additional information about AcelRx, please visit www.acelrx.com.
SOURCE AcelRx Pharmaceuticals, Inc.
Related Links
www.acelrx.com
Filed Under: Business
0 Comments
Latest on The Californer
- Eric Bellinger Hosts Second Annual Christmas Hoopathon Benefiting Underserved Youth
- ECMG Releases Doom to the World: A Cthulhu Holiday Album (Volume 1)
- California: Governor Newsom proclaims state of emergency to support response in multiple counties due to late December storms
- eJoule Inc Participates in Silicon Dragon CES 2026
- City of Long Beach Issues Rain Advisory Due to Recent Showers
- PODS Local Helps Residents Meet Their 2026 New Year's Resolution
- HBZBZL Unveils "Intelligent Ecosystem" Strategy: Integrating AI Analytics with Web3 Incubation
- Kaltra Launches Next-Gen MCHEdesign With Full Integration Into MCHEselect — Instant Simulation & Seamless Microchannel Coil Workflow
- Nexar Bit Exchange Enhances Platform Infrastructure
- Jon Robert Quinn Builds Awepra, AwepraAI, and AwepraQ to Redefine the Future Beyond Social Media
- A Well-Fed World, Youth Climate Save and PAN International Launch PHRESH: A Global Directory of Plant-Based Hunger Relief Organizations
- 4-Hour Work Day: Jon Robert Quinn Challenges Hustle Culture and Redefines Entrepreneurial Success
- Long Beach: City Announces Conclusion of SEED Program Following Loss of Federal Funding, Launches LBPL Creativity Lab
- Long Beach Health Department Launches Expanded Fund Initiatives to Support Community Health and Local Nonprofits
- California turns winter season rain into future water supply
- City of Long Beach Extends Inclement Weather Action Plans
- Louisa Gillis at North Coast Repertory Theatre
- California: Governor Newsom declares states of emergency related to multiple severe weather events in 2025
- California: Governor Newsom deploys dedicated teams to fight crime in Stockton, building on existing successful partnerships
- BanksyLee.com Is Redefining Daily Financial Insight for the Modern Investor